



<!DOCTYPE html><html lang="de"><head><title>New First-in-Class Phase 3 TREMFYA? (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52</title><link rel="dns-prefetch" href="//fns1.de" /><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="keywords" content="First, Class, Phase, TREMFYA, guselkumab, Data, Demonstrate, Improvement, Psoriatic, Arthritis, Joint, Skin, Symptoms, Week" /><meta name="description" content=" Findings from the DISCOVER-1 and DISCOVER-2 studies presented at the 2020 European League Against Rheumatism E-Congress These are the first one-year Phase 3 results evaluating p19 subunit-specific" /><meta name="robots" content="noodp,index,follow" /><meta property="og:title" content="New First-in-Class Phase 3 TREMFYA? (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52" /><meta property="og:url" content="https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm" /><meta property="og:site_name" content="FinanzNachrichten.de" /><meta property="og:image" content="https://fns1.de/g/fb.png" /><meta property="og:type" content="article" /><meta property="og:description" content=" Findings from the DISCOVER-1 and DISCOVER-2 studies presented at the 2020 European League Against Rheumatism E-Congress These are the first one-year Phase 3 results evaluating p19 subunit-specific" /><meta property="fb:admins" content="100001851463444" /><link rel="canonical" href="https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm" /><meta name="apple-itunes-app" content="app-id=576714727" /><meta name="google-play-app" content="app-id=de.finanznachrichten.app"><meta name="viewport" content="width=device-width, initial-scale=1"><link rel="shortcut icon" href="https://fns1.de/g/favicon.ico" /><link rel="search" type="application/opensearchdescription+xml" title="FinanzNachrichten.de Suche" href="https://fns1.de/suche/fn-osd-2.xml" /><link href="http://www.finanznachrichten.de/rss-aktien-nachrichten/" title="Aktuelle Nachrichten" type="application/rss+xml" rel="alternate" /><link href="http://www.finanznachrichten.de/rss-aktien-analysen/" title="Aktienanalysen" type="application/rss+xml" rel="alternate" /><link href="http://www.finanznachrichten.de/rss-aktien-adhoc/" title="Ad hoc-Mitteilungen" type="application/rss+xml" rel="alternate" /><link href="http://www.finanznachrichten.de/rss-news/" title="Englischsprachige Nachrichten" type="application/rss+xml" rel="alternate" /><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/bootswatch/3.4.0/yeti/bootstrap.min.css" integrity="sha256-ICOIXkZvfEjsPIVGgvAVTRNsYQbRELh04MoGaItVyuw=" crossorigin="anonymous" /><link href="https://fns1.de/css/fn211.css" rel="stylesheet" /><!-- Global site tag (gtag.js) - Google Analytics --><script async src="https://www.googletagmanager.com/gtag/js?id=UA-55465-3"></script><script>window.dataLayer = window.dataLayer || []; function gtag() { dataLayer.push(arguments); } gtag('js', new Date()); gtag('config', 'UA-55465-3', { 'anonymize_ip': true });</script><script type="text/javascript" src="//cpanel.nativeads.com/js/nativeads-0-4b761dde1a4ca826c759db5ff639bd44cea43ba8.js" async></script><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery-migrate/3.0.1/jquery-migrate.min.js" integrity="sha256-F0O1TmEa4I8N24nY0bya59eP6svWcshqX1uzwaWC4F4=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/OwlCarousel2/2.3.4/owl.carousel.min.js" integrity="sha256-pTxD+DSzIwmwhOqTFN+DB+nHjO4iAsbgfyFq5K5bcE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.0/js/bootstrap.min.js" integrity="sha256-kJrlY+s09+QoWjpkOrXXwhxeaoDz9FW5SaxF8I0DibQ=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.26.0/moment-with-locales.min.js" integrity="sha256-4HOrwHz9ACPZBxAav7mYYlbeMiAL0h6+lZ36cLNpR+E=" crossorigin="anonymous"></script><script type="text/javascript" async>var elem = document.createElement('script');
        elem.src = 'https://quantcast.mgr.consensu.org/cmp.js';
        elem.async = true;
        elem.type = "text/javascript";
        var scpt = document.getElementsByTagName('script')[0];
        scpt.parentNode.insertBefore(elem, scpt);
        (function () {
            var gdprAppliesGlobally = true;
            function addFrame() {
                if (!window.frames['__cmpLocator']) {
                    if (document.body) {
                        var body = document.body,
                            iframe = document.createElement('iframe');
                        iframe.style = 'display:none';
                        iframe.name = '__cmpLocator';
                        body.appendChild(iframe);
                    } else {
                        // In the case where this stub is located in the head,
                        // this allows us to inject the iframe more quickly than
                        // relying on DOMContentLoaded or other events.
                        setTimeout(addFrame, 5);
                    }
                }
            }
            addFrame();
            function cmpMsgHandler(event) {
                var msgIsString = typeof event.data === "string";
                var json;
                if (msgIsString) {
                    json = event.data.indexOf("__cmpCall") != -1 ? JSON.parse(event.data) : {};
                } else {
                    json = event.data;
                }
                if (json.__cmpCall) {
                    var i = json.__cmpCall;
                    window.__cmp(i.command, i.parameter, function (retValue, success) {
                        var returnMsg = {
                            "__cmpReturn": {
                                "returnValue": retValue,
                                "success": success,
                                "callId": i.callId
                            }
                        };
                        event.source.postMessage(msgIsString ?
                            JSON.stringify(returnMsg) : returnMsg, '*');
                    });
                }
            }
            window.__cmp = function (c) {
                var b = arguments;
                if (!b.length) {
                    return __cmp.a;
                }
                else if (b[0] === 'ping') {
                    b[2]({
                        "gdprAppliesGlobally": gdprAppliesGlobally,
                        "cmpLoaded": false
                    }, true);
                } else if (c == '__cmp')
                    return false;
                else {
                    if (typeof __cmp.a === 'undefined') {
                        __cmp.a = [];
                    }
                    __cmp.a.push([].slice.apply(b));
                }
            }
            window.__cmp.gdprAppliesGlobally = gdprAppliesGlobally;
            window.__cmp.msgHandler = cmpMsgHandler;
            if (window.addEventListener) {
                window.addEventListener('message', cmpMsgHandler, false);
            }
            else {
                window.attachEvent('onmessage', cmpMsgHandler);
            }
        })();
        window.__cmp('init', {
            'Language': 'de',
            'Initial Screen Title Text': 'Wir respektieren Ihre Privatsphäre',
            'Initial Screen Reject Button Text': 'ICH STIMME NICHT ZU',
            'Initial Screen Accept Button Text': 'ICH STIMME ZU',
            'Initial Screen Purpose Link Text': 'Zwecke anzeigen',
            'Purpose Screen Title Text': 'Wir respektieren Ihre Privatsphäre',
            'Purpose Screen Body Text': 'Sie können Ihre Einwilligungsvorgaben festlegen und bestimmen, wie Ihre Daten basierend auf den folgenden Zwecken verwendet werden sollen. Sie können Ihre Einstellungen für uns unabhängig von denen von Drittanbietern vornehmen. Jeder Zweck hat eine Beschreibung, damit Sie wissen, wie wir und unsere Partner Ihre Daten verwenden.',
            'Purpose Screen Vendor Link Text': 'Anbieter anzeigen',
            'Purpose Screen Cancel Button Text': 'Abbrechen',
            'Purpose Screen Save and Exit Button Text': 'Speichern &amp; verlassen',
            'Vendor Screen Title Text': 'Wir respektieren Ihre Privatsphäre',
            'Vendor Screen Body Text': 'Im Folgenden können Sie Einwilligungsvorgaben für einzelne Drittanbieter festlegen, mit denen wir zusammenarbeiten. Zur Erleichterung Ihrer Auswahl können Sie die einzelnen Einträge auf der Unternehmensliste erweitern, um zu sehen, für welche Zwecke sie Daten verwenden. In einigen Fällen können Unternehmen Ihre Daten aufgrund ihrer berechtigten Interessen verwenden, ohne Sie um Ihre Zustimmung zu bitten. Sie können auf deren Datenschutzrichtlinien-Links klicken, um weitere Informationen zu erhalten und einer solchen Verarbeitung zu widersprechen.',
            'Vendor Screen Accept All Button Text': 'ALLE AKZEPTIEREN',
            'Vendor Screen Reject All Button Text': 'ALLE ABLEHNEN',
            'Vendor Screen Purposes Link Text': 'Zurück zu den Zwecken',
            'Vendor Screen Cancel Button Text': 'Abbrechen',
            'Vendor Screen Save and Exit Button Text': 'Speichern &amp; verlassen',
            'Initial Screen Body Text': 'Wir und unsere Partner verwenden Technologien wie Cookies und verarbeiten personenbezogene Daten wie IP-Adressen und Cookie-IDs, um Anzeigen und Inhalte auf Grundlage Ihrer Interessen zu personalisieren, die Leistung von Anzeigen und Inhalten zu messen und Erkenntnisse über die Zielgruppen zu gewinnen, die Anzeigen und Inhalte gesehen haben. Klicken Sie unten, um der Verwendung dieser Technologie und der Verarbeitung Ihrer persönlichen Daten für diese Zwecke zuzustimmen. Sie können Ihre Meinung und Ihre Einwilligungsentscheidungen jederzeit ändern, indem Sie auf diese Website zurückkehren.',
            'Initial Screen Body Text Option': 1,
            'Consent Scope': 'service',
            'Display UI': 'always',
            'Publisher Purpose IDs': [1, 2, 3, 4, 5],
            'Publisher Name': 'FinanzNachrichten',
            'Publisher Logo': 'https://fns1.de/img/logo.svg',
            'Post Consent Page': 'https://www.finanznachrichten.de/service/impressum.htm',
            'UI Layout': 'banner',
        });</script><meta property="og:image" content="https://cts.businesswire.com/ct/CT?id=bwnews&sty=20200603005461r1&sid=gefi2&distro=ftp" /><script>(function () {
                var s = document.createElement('script');
                s.type = 'text/javascript';
                s.async = true;
                s.src = '//d.finative.eu/d/init';
                var sc = document.getElementsByTagName('script')[0];
                sc.parentNode.insertBefore(s, sc);
            })();</script><script type="text/javascript" src="//ads.vidoomy.com/finanznachrichten_6496.js"></script></head><body id="artikel_index" itemscope itemtype="https://schema.org/WebPage" class="l-xl"><div id="fb-root"></div><div id="mantel"><aside id="slide-out"></aside><div id="sideteaser"><div class="anzeige">Anzeige</div><div class="close">&#10060;</div><div class="headline"></div><div class="text"></div><img class="image" /><div class="more">Mehr »</div></div><div id="adspacer"></div><div id="inhalt" class="inner-wrapper small-header"><div id="fnk"><div id="fn-lf"></div><a id="btn-login" class="slide-out-open" href="https://www.finanznachrichten.de/watchlist/login.htm"><i class="icon fn-icon-torso"></i>Login</a><div class="fn-mobile-logo"><a title="Aktuelle Nachrichten zu Aktien, Börse und Finanzen" href="https://www.finanznachrichten.de/"><img src="https://fns1.de/img/logo.svg" alt="FinanzNachrichten.de" /></a></div><a id="slide-out-open" class="slide-out-open" href="#"><span></span></a><div id="fn-mc-ph"></div><div class="clear"></div><div id="main-nav" class="fixed-enabled"><nav id="navigation"><div class="main-menu novibrant"><div class="ul menu"><div class="menu-item menu-item-home"><a title="Aktuelle Nachrichten zu Aktien, Börse und Finanzen" href="https://www.finanznachrichten.de/">Startseite</a></div><div class="menu-item menu-item-has-children mega-menu mega-links "><a href="https://www.finanznachrichten.de/nachrichten/uebersicht.htm">Nachrichten</a><div class="mega-menu-block menu-sub-content"><div class="ul sub-menu-columns"><div class="menu-item menu-item-has-children"><a class="menue-heading" href="#">Nachrichten</a><div class="ul sub-menu-columns-item navi2col"><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/news.htm">Nachrichten auf FN</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/nachrichten-alle.htm">Alle News</a></div></div><i class="mobile-arrows icon fn-icon-down-open"></i></div><div class="menu-item menu-item-has-children"><a class="menue-heading" href="#">Rubriken</a><div class="ul sub-menu-columns-item navi2col"><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/aktien-blickpunkt.htm">Aktien im Blickpunkt</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/ad-hoc-mitteilungen.htm">Ad hoc-Mitteilungen</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/bestbewertete-news.htm">Bestbewertete News</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/top-news.htm">Meistgelesene News</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/konjunktur-news.htm">Konjunktur- und Wirtschaftsnews</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/marktberichte.htm">Marktberichte</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/empfehlungen.htm">Empfehlungsübersicht</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/alle-empfehlungen.htm">Alle Aktienempfehlungen</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/chartanalysen.htm">Chartanalysen</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/ipo-nachrichten.htm">IPO-News</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/termine.htm">Termine</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/dossiers/uebersicht.htm">Themen-Dossiers</a></div></div><i class="mobile-arrows icon fn-icon-down-open"></i></div><div class="menu-item menu-item-has-children"><a class="menue-heading" href="#">Indizes</a><div class="ul sub-menu-columns-item navi4col"><div class="menu-item full-width"><a title="Alle Indizes in der Übersicht" href="https://www.finanznachrichten.de/nachrichten-index/uebersicht.htm">Übersicht nach Indizes/Märkten</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten-index/dax-30.htm"><span class="sprite flagge de"></span>DAX</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten-index/sdax.htm"><span class="sprite flagge de"></span>SDAX</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten-index/mdax.htm"><span class="sprite flagge de"></span>MDAX</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten-index/tecdax.htm"><span class="sprite flagge de"></span>TecDAX</a></div><div class="menu-item clr fliess"><a href="https://www.finanznachrichten.de/nachrichten-index/dj-industrial.htm"><span class="sprite flagge us"></span>DJIA</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten-index/s-p-500.htm"><span class="sprite flagge us"></span>S&amp;P 500</a></div><div class="menu-item half-width"><a href="https://www.finanznachrichten.de/nachrichten-index/nasdaq-100.htm"><span class="sprite flagge us"></span>NASDAQ 100</a></div><div class="menu-item clr fliess"><a href="https://www.finanznachrichten.de/nachrichten-index/euro-stoxx-50.htm"><span class="sprite flagge eu"></span>EURO STOXX 50</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten-index/ftse-100.htm"><span class="sprite flagge gb"></span>FTSE-100</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten-index/smi.htm"><span class="sprite flagge ch"></span>SMI</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten-index/atx.htm"><span class="sprite flagge at"></span>ATX</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten-index/nikkei-225.htm"><span class="sprite flagge jp"></span>NIKKEI</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten-index/hang-seng.htm"><span class="sprite flagge cn"></span>HANG SENG</a></div></div><i class="mobile-arrows icon fn-icon-down-open"></i></div><div class="menu-item menu-item-has-children"><a class="menue-heading" href="#">Branchen</a><div class="ul sub-menu-columns-item navi2col"><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten-branche/uebersicht.htm">Branchenübersicht</a></div></div><i class="mobile-arrows icon fn-icon-down-open"></i></div><div class="menu-item menu-item-has-children"><a class="menue-heading" href="#">Medien</a><div class="ul sub-menu-columns-item navi2col"><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten-medien/uebersicht.htm">Medienübersicht</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/nachrichten/suche-medienarchiv.htm">Archiv</a></div></div><i class="mobile-arrows icon fn-icon-down-open"></i></div><div class="menu-item"><a href="https://www.finanznachrichten.de/suche/uebersicht.htm">Erweiterte Suche</a></div></div></div><i class="mobile-arrows icon fn-icon-down-open"></i></div><div class="menu-item menu-item-has-children mega-menu mega-links "><a href="https://www.finanznachrichten.de/aktienkurse/uebersicht.htm">Aktienkurse</a><div class="mega-menu-block menu-sub-content"><div class="ul sub-menu-columns"><div class="menu-item menu-item-has-children"><a class="menue-heading" href="#">Aktienkurse</a><div class="ul sub-menu-columns-item navi2col"><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse/realtime-kurse.htm">Realtime-Aktienkursliste (L&amp;S)</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/online-broker-vergleich.htm">Online-Broker-Vergleich</a></div></div><i class="mobile-arrows icon fn-icon-down-open"></i></div><div class="menu-item menu-item-has-children"><a class="menue-heading" href="#">XETRA-Orderbuch</a><div class="ul sub-menu-columns-item navi2col"><div class="menu-item"><a href="https://aktienkurs-orderbuch.finanznachrichten.de/">Übersicht</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/xetra-orderbuch.htm">XETRA-Orderbuch?</a></div></div><i class="mobile-arrows icon fn-icon-down-open"></i></div><div class="menu-item menu-item-has-children"><a class="menue-heading" href="#">Indizes</a><div class="ul sub-menu-columns-item navi4col"><div class="menu-item full-width"><a href="https://www.finanznachrichten.de/aktienkurse/indizes.htm">Indexliste</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-index/dax-30.htm"><span class="sprite flagge de"></span>DAX</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-index/sdax.htm"><span class="sprite flagge de"></span>SDAX</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-index/mdax.htm"><span class="sprite flagge de"></span>MDAX</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-index/tecdax.htm"><span class="sprite flagge de"></span>TecDAX</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-index/dj-industrial.htm"><span class="sprite flagge us"></span>DJIA</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-index/s-p-500.htm"><span class="sprite flagge us"></span>S&amp;P 500</a></div><div class="menu-item half-width"><a href="https://www.finanznachrichten.de/aktienkurse-index/nsadaq-100.htm"><span class="sprite flagge us"></span>NASDAQ 100</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-index/euro-stoxx-50.htm"><span class="sprite flagge eu"></span>EURO STOXX 50</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-index/ftse-100.htm"><span class="sprite flagge gb"></span>FTSE-100</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-index/smi.htm"><span class="sprite flagge ch"></span>SMI</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-index/atx.htm"><span class="sprite flagge at"></span>ATX</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-index/nikkei-225.htm"><span class="sprite flagge jp"></span>NIKKEI</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-index/hang-seng.htm"><span class="sprite flagge cn"></span>HANG SENG</a></div></div><i class="mobile-arrows icon fn-icon-down-open"></i></div><div class="menu-item menu-item-has-children"><a class="menue-heading" href="#">Branchen</a><div class="ul sub-menu-columns-item navi4col"><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/uebersicht.htm">Branchenübersicht</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/bau-infrastruktur.htm">Bau / Infrastrukur</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/bekleidung-textil.htm">Bekleidung / Textil</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/biotechnologie.htm">Biotechnologie</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/chemie.htm">Chemie</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/dienstleistungen.htm">Dienstleistungen</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/eisen-stahl.htm">Eisen / Stahl</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/elektrotechnologie.htm">Elektrotechnologie</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/erneuerbare-energien.htm">Erneuerbare Energien</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/fahrzeuge.htm">Fahrzeuge</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/finanzdienstleistungen.htm">Finanzdienstleistungen</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/freizeitprodukte.htm">Freizeitprodukte</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/gesundheitswesen.htm">Gesundheitswesen</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/getraenke-tabak.htm">Getränke / Tabak</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/halbleiter.htm">Halbleiter</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/handel-e-commerce.htm">Handel / E-Commerce</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/hardware.htm">Hardware</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/holz-papier.htm">Holz / Papier</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/hotels-tourismus.htm">Hotels / Tourismus</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/immobilien.htm">Immobilien</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/industrie-mischkonzerne.htm">Industrie / Mischkonzerne</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/internet.htm">Internet</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/it-dienstleistungen.htm">IT-Dienstleistungen</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/konsumgueter.htm">Konsumgüter</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/kosmetik.htm">Kosmetik</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/kunststoffe-verpackungen.htm">Kunststoffe / Verpackungen</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/logistik-transport.htm">Logistik / Transport</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/luftfahrt-ruestung.htm">Luftfahrt / Rüstung</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/maschinenbau.htm">Maschinenbau</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/medien.htm">Medien</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/nanotechnologie.htm">Nanotechnologie</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/nahrungsmittel-agrar.htm">Nahrungsmittel / Agrar</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/netzwerktechnik.htm">Netzwerktechnik</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/oel-gas.htm">Öl / Gas</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/pharma.htm">Pharma</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/rohstoffe.htm">Rohstoffe</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/software.htm">Software</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/sonstige-technologie.htm">Sonstige Technologie</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/telekom.htm">Telekommunikation</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/unterhaltung.htm">Unterhaltung</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/aktienkurse-branche/versorger.htm">Versorger</a></div></div><i class="mobile-arrows icon fn-icon-down-open"></i></div></div></div><i class="mobile-arrows icon fn-icon-down-open"></i></div><div class="menu-item  "><a href="https://www.finanznachrichten.de/fonds/uebersicht.htm"><i class="icon fn-icon-banknote"></i>Fonds</a></div><div class="menu-item  "><a href="https://www.finanznachrichten.de/anleihen/uebersicht.htm"><i class="icon fn-icon-banknote"></i>Anleihen</a></div><div class="menu-item  "><a href="https://www.finanznachrichten.de/derivate/uebersicht.htm"><i class="icon fn-icon-banknote"></i>Derivate</a></div><div class="menu-item  "><a href="https://www.finanznachrichten.de/rohstoffe/uebersicht.htm"><i class="icon fn-icon-science-laboratory"></i>Rohstoffe</a></div><div class="menu-item menu-item-has-children mega-menu mega-links"><a href="https://www.finanznachrichten.de/devisen/uebersicht.htm"><i class="icon fn-icon-banknote"></i>Devisen</a><div class="mega-menu-block menu-sub-content"><div class="ul sub-menu-columns navi2col"><div class="menu-item full-width"><a title="Kryptowährungen" href="https://www.finanznachrichten.de/devisen/krypto-waehrungen.htm">Kryptowährungen</a></div></div></div><i class="mobile-arrows icon fn-icon-down-open"></i></div><div class="menu-item menu-item-has-children mega-menu mega-links"><a href="https://www.finanznachrichten.de/watchlist/nachrichten.htm"><i class="icon fn-icon-magnifying-glass"></i>Watchlist</a><div class="mega-menu-block menu-sub-content"><div class="ul sub-menu-columns navi2col"><div class="menu-item"><a href="https://www.finanznachrichten.de/watchlist/anlegen.htm">Watchlist anlegen</a></div><div class="menu-item"><a href="https://www.finanznachrichten.de/watchlist/information.htm">Was bringt eine Nachrichten-Watchlist?</a></div></div></div><i class="mobile-arrows icon fn-icon-down-open"></i></div></div></div></nav></div><div class="suche-mobile novibrant"><i class="icon fn-icon-magnifying-glass"></i></div><form action="https://www.finanznachrichten.de/suche/uebersicht.htm" method="get" id="fnkSucheForm" class="fnForm novibrant"><div id="sb-info"><span id="sb-datum">Freitag, 12.06.2020</span> Börsentäglich
        über 12.000 News von 631 internationalen
        Medien</div><div id="fnk-suche-cont"><div id="fnkSucheInputRow"><a id="fnkSucheErwL" class="fnChrome extendedSearch" href="https://www.finanznachrichten.de/suche/uebersicht.htm" data-baseurl="https://www.finanznachrichten.de/suche/uebersicht.htm?suche="><i class="icon fn-icon-search"></i>Erweiterte<br />Suche</a><i class="icon fn-icon-magnifying-glass"></i><input type="text" class="fnTextInput" id="fnk-suche-eingabe" accesskey="s" name="suche" required="required" /><input type="submit" id="fnk-suche-absenden" value="Suchen" /></div><div id="suchfeld-auto-vervollstaendigen" class="auto-vervollstaendigen"><div id="fnk-suche-werb"><span class="nadT extern href cursor_pointer" title="Gro&#223; eingekauft - Milliard&#228;rin investiert in diesen Pennystock!" data-nid="0" data-nad="796">Gro&#223; eingekauft - Milliard&#228;rin investiert in diesen Pennystock!</span><div>Anzeige</div></div><table id="suchhilfeListe" class="suchHilfe"><tbody data-type="Indizes"><tr class="deco"><th class="sh-flagge"></th><th class="sh-prettyname"><br />Indizes</th><th class="sh-kurs"><br />Kurs</th><th class="sh-kurs"><br />%</th><th class="sh-news">News<br />24&nbsp;h&nbsp;/&nbsp;7&nbsp;T</th><th class="sh-aufrufe">Aufrufe<br />7 Tage</th></tr><tr class="row_spacer"><td></td></tr><tr class="hoverable template"><td class="sh-flagge"></td><td class="sh-prettyname"><span title=""></span></td><td class="sh-kurs"></td><td class="sh-kurs"></td><td class="sh-news"></td><td class="sh-aufrufe"></td></tr></tbody><tbody data-type="Aktien"><tr class="deco"><th class="sh-flagge"></th><th class="sh-prettyname"><br />Aktien</th><th class="sh-kurs"><br />Kurs</th><th class="sh-kurs"><br />%</th><th class="sh-news">News<br />24&nbsp;h&nbsp;/&nbsp;7&nbsp;T</th><th class="sh-aufrufe">Aufrufe<br />7 Tage</th></tr><tr class="row_spacer"><td></td></tr><tr class="hoverable template"><td class="sh-flagge"></td><td class="sh-prettyname"><span title=""></span></td><td class="sh-kurs"></td><td class="sh-kurs"></td><td class="sh-news"></td><td class="sh-aufrufe"></td></tr></tbody><tbody data-type="Orderbuch"><tr class="deco"><th class="sh-flagge"></th><th class="sh-prettyname colspan"><br />Xetra-Orderbuch</th><th class="sh-kurs"></th><th class="sh-kurs"></th><th class="sh-news"></th><th class="sh-aufrufe"></th></tr><tr class="row_spacer"><td></td></tr><tr class="hoverable template"><td class="sh-flagge"></td><td class="sh-prettyname colspan"><span title=""></span></td><td class="sh-kurs"></td><td class="sh-kurs"></td><td class="sh-news"></td><td class="sh-aufrufe"></td></tr></tbody><tbody data-type="Devisen"><tr class="deco"><th class="sh-flagge"></th><th class="sh-prettyname"><br />Devisen</th><th class="sh-kurs"><br />Kurs</th><th class="sh-kurs"><br />%</th><th class="sh-news"></th><th class="sh-aufrufe"></th></tr><tr class="row_spacer"><td></td></tr><tr class="hoverable template"><td class="sh-flagge"></td><td class="sh-prettyname"><span title=""></span></td><td class="sh-kurs"></td><td class="sh-kurs"></td><td class="sh-news"></td><td class="sh-aufrufe"></td></tr></tbody><tbody data-type="Rohstoffe"><tr class="deco"><th class="sh-flagge"></th><th class="sh-prettyname"><br />Rohstoffe</th><th class="sh-kurs"><br />Kurs</th><th class="sh-kurs"><br />%</th><th class="sh-news"></th><th class="sh-aufrufe"></th></tr><tr class="row_spacer"><td></td></tr><tr class="hoverable template"><td class="sh-flagge"></td><td class="sh-prettyname"><span title=""></span></td><td class="sh-kurs"></td><td class="sh-kurs"></td><td class="sh-news"></td><td class="sh-aufrufe"></td></tr></tbody><tbody data-type="Dossier"><tr class="deco"><th class="sh-flagge"></th><th class="sh-prettyname"><br />Themen</th><th class="sh-kurs"><br />Kurs</th><th class="sh-kurs"><br />%</th><th class="sh-news"></th><th class="sh-aufrufe"></th></tr><tr class="row_spacer"><td></td></tr><tr class="hoverable template"><td class="sh-flagge"></td><td class="sh-prettyname"><span title=""></span></td><td class="sh-kurs"></td><td class="sh-kurs"></td><td class="sh-news"></td><td class="sh-aufrufe"></td></tr></tbody><tbody class="show"><tr class="row_spacer"><td></td></tr><tr><td class="sh-prettyname" colspan="6"><br /><a style="margin-left:20px;" class="fett extendedSearch" href="https://www.finanznachrichten.de/suche/uebersicht.htm" data-baseurl="https://www.finanznachrichten.de/suche/uebersicht.htm?suche=">Erweiterte Suche</a></td></tr></tbody></table></div></div></form><div id="sb-adhoc"><div id="sb-adhoc-bez"><strong><a class="fnChrome" href="https://www.finanznachrichten.de/nachrichten/ad-hoc-mitteilungen.htm">Ad hoc-Mitteilungen</a></strong>:</div><div id="sb-adhoc-mrq"><div id="sb-adhoc-mrq-c"><div id="sb-adhoc-mrq-s" class="marquee"><div id="sb-adhoc-mrq-sp" style="display: inline-block;"></div></div></div></div></div></div><div id="brotKrumen" class="bkContainer"><div id="bk" class="norm" itemprop="breadcrumb"><a rel="home" href="https://www.finanznachrichten.de/" title="FinanzNachrichten.de"><span class="sprite fn_vorstand icon_fn"></span></a><span><a href="https://www.finanznachrichten.de/nachrichten/uebersicht.htm" title="Nachrichten"><span>Nachrichten</span></a><span class="brot">&raquo;</span><span><a href="https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm" title="New First-in-Class Phase 3 TREMFYA? (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52"><span>New First-in-Class Phase 3 TREMFYA? (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52</span></a></span></span></div><div id="ls"><span id="fn-als-startseite"><a href="https://www.finanznachrichten.de/service/fnalsstartseite.htm" title="Keine Nachrichten mehr verpassen: FinanzNachrichten.de zur Startseite machen">FN als Startseite</a></span><span id="RealtimeStatusSchalter" title="Hier klicken, um Realtime-Push-Kurse ein- oder auszuschalten"></span></div></div><div class="hinweis-a"><div class="sprite hinweis-b"></div><div id='dban1'></div><div id='sban1'></div><div id='yoc_top_HB'></div></div><div id="seitenbereiche"
     data-apihost="m.finanznachrichten.de"
     data-wsokw=""
     data-wsopid="artikel_index_49826080"
     data-wsores="News"
     data-wsorub="News"
     data-wsourl="www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm"
     data-wsolay="Detailseite"
     data-wsotag="nachrichten"
     data-netpointfooter="False"><div class="sbSpalteL"><div class="seitenelement Nachrichten_Artikel poslinks" id="W459" data-hasrealtime="False"><div id="artikel_data" class="data" data-aktienzurnachricht="[]"></div><div itemscope="itemscope" itemtype="http://schema.org/Article"><meta itemprop="url" content="https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm" /><meta itemprop="author" content="Business Wire" /><meta itemprop="datePublished" content="2020-06-03T14:34" /><meta itemprop="interactionCount" content="UserPageVisits:121" /><meta itemprop="keywords" content="First Class Phase TREMFYA guselkumab Data Demonstrate Improvement Psoriatic Arthritis Joint Skin Symptoms Week" /><meta itemprop="publisher" content="https://www.finanznachrichten.de" /><meta itemprop="headline" content="New First-in-Class Phase 3 TREMFYA? (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52" /><div id="article--rating-data" class="data" data-nachrichtid="49826080" data-cssclass="unbewertet" data-feedurl="https://www.finanznachrichten.de/nachrichten-medien/business-wire.htm"></div><div id="article--header"><a href="https://www.finanznachrichten.de/nachrichten-medien/business-wire.htm"><strong>Business Wire</strong></a><div class="article--date-time">03.06.2020 | 14:34</div><div class="article--reader-count">121 Leser</div><div id="article--rating">Artikel bewerten:<div class="rateit" id="article--rating-stars" title=""
                        data-rateit-value="0" data-rateit-resetable="false"
                        data-rateit-readonly="true" data-rateit-starwidth="12" data-rateit-starheight="12"></div><div id="article--rating-star-title"></div><div id="article--rating-title">(0)</div></div></div><h1 class="article--headline"><a href='https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm'>New First-in-Class Phase 3 TREMFYA? (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52</a></h1><div class="inhalte-text"><div itemprop="articleBody" id="artikelText" class="f_business-wire"><div id="artikelTextPuffer"><p class="bwalignc">  		<i>Findings from the DISCOVER-1 and DISCOVER-2 studies presented at the 2020 European League Against Rheumatism E-Congress</i></p>  	<p class="bwalignc">  		<i>These are the first one-year Phase 3 results evaluating p19 subunit-specific IL-23 inhibition in active psoriatic arthritis </i></p><p>The Janssen Pharmaceutical Companies of Johnson Johnson today announced new data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2, which showed that TREMFYA<sup></sup><b></b> (guselkumab) demonstrated improvements in multiple clinical outcomes including joint symptoms, skin symptoms, soft tissue inflammation, physical function and reduction in radiographic progression at week 52 in adult patients with active psoriatic arthritis (PsA).<sup>1,2 </sup>Guselkumab is currently not licensed for the treatment of PsA and is undergoing evaluation for this use by the European Medicines Agency (EMA). Data from the two studies in the DISCOVER programme formed the basis of the validated filing on 11 October 2019 to the EMA in the European Union (EU) for approval of guselkumab for the treatment of adult patients with active PsA<sup></sup>and primary endpoint results were recently published in <i>The Lancet</i>.<sup>3,4,5</sup></p>  	<p>"Those who are living with active psoriatic arthritis are faced with debilitating symptoms and inflammation which may ultimately lead to irreversible damage to the joints," said Christopher Ritchlin<sup></sup>, M.D., M.P.H., Chief of the Division of Allergy, Immunology and Rheumatology and Director of the Clinical Immunology Research Center at the University of Rochester Medical Center in Rochester, New York and lead investigator of the DISCOVER-1 study. "Findings from the DISCOVER-1 and DISCOVER-2 studies are encouraging for patients and physicians alike who may be seeking new treatment options that utilise mechanisms of action different to anti-tumour necrosis factor (TNF) alpha biologics to combat the multi-faceted combination of symptoms presented by psoriatic arthritis."
</p>  	<p>DISCOVER-1 and DISCOVER-2 evaluated the efficacy and safety of guselkumab compared to placebo. DISCOVER-1 included patients who were biologic-naïve or had previously been exposed to anti-TNF alpha biologics. DISCOVER-2 included patients who were biologic-naïve only; it also assessed radiographic progression of joint damage. In both studies, patients were randomised to guselkumab 100 mg every 4 weeks (q4w) or every 8 weeks (q8w) for one year, or to placebo with crossover to guselkumab q4w at week 24 through one year. These findings are being presented as poster tours (SAT0397/SAT0402) at this year's European League Against Rheumatism (EULAR) E-Congress, at which Janssen is sharing data in a total of 32 abstracts.<sup>1,2</sup></p>  	<p>In both studies, American College of Rheumatology (ACR) response rates at week 52 included non-responder imputation (NRI) data, which categorised patients who discontinued the study as non-responders from week 24 to 52.
</p>  	<p>In DISCOVER-1, data demonstrated that at week 52:<sup>1</sup></p>  	<ul class="bwlistdisc">  		<li>73 percent of guselkumab q4w patients and 60 percent of guselkumab q8w patients achieved ACR20; 54 percent of guselkumab q4w patients and 39 percent of guselkumab q8w patients achieved ACR50 (NRI).
</li></ul>  	<ul class="bwlistdisc">  		<li>Among patients who had clinically relevant psoriasis at baseline, 83 percent of guselkumab q4w patients, 69 percent of guselkumab q8w patients and 82 percent of patients who crossed over from placebo to guselkumab q4w achieved clear or almost clear skin with at least a 2 grade improvement from baseline as measured by the Investigator Global Assessment (IGA) score (observed data).<sup>a</sup></li></ul>  	<p>In DISCOVER-2, data demonstrated that at week 52:<sup>2</sup></p>  	<ul class="bwlistdisc">  		<li>71 percent of guselkumab q4w patients and 75 percent of guselkumab q8w patients achieved ACR20; 46 percent of guselkumab q4w patients and 48 percent of guselkumab q8w patients achieved ACR50 (NRI).
</li></ul>  	<ul class="bwlistdisc">  		<li>Among patients who had clinically relevant psoriasis at baseline, 84 percent of guselkumab q4w patients, 77 percent of guselkumab q8w patients and 84 percent of patients who crossed over from placebo to guselkumab q4w achieved clear or almost clear skin with at least a 2 grade improvement from baseline as measured by the IGA score (observed data).<sup>a</sup></li></ul>  	<ul class="bwlistdisc">  		<li>Guselkumab q4w and q8w demonstrated sustained improvements in inhibition of radiographic progression<sup>b</sup> of joint structural damage through week 52 (observed data).
</li></ul>  	<p>The DISCOVER studies also showed improvements in multiple secondary endpoints at week 52 compared with week 24,<sup>1,2</sup> including ACR70 response, resolution of soft tissue inflammation (enthesitis and dactylitis)<sup>c,d</sup>, disease activity score (DAS-28) (C-Reactive Protein [CRP])<sup>e</sup> (minimal disease activity [MDA])<sup>f</sup> (very low disease activity [VLDA])<sup>g</sup>, improvement in physical function (Health Assessment Questionnaire Disability Index [HAQ-DI])<sup>h</sup>, general health outcomes (SF-36 Physical Component Summary [PCS] and Mental Component Summary [MCS]).<sup>i,j,k</sup></p>  	<p>In both studies, guselkumab was well-tolerated through study completion, and observed adverse events (AEs) were generally consistent with previous studies of guselkumab and current prescribing information.<sup>6</sup> Serious AEs and serious infections occurred in 4 percent and 1 percent of guselkumab-treated patients, respectively, in both DISCOVER-1 and DISCOVER-2. There were no reported deaths in guselkumab-treated patients and no guselkumab-treated patient had inflammatory bowel disease, opportunistic infections, active tuberculosis or anaphylactic or serum sickness-like reactions.<sup>1,2</sup></p>  	<p>"Efficacy of guselkumab in psoriatic arthritis was previously demonstrated to be superior to placebo at week 24. These new data show that efficacy is maintained to week 52 with safety data that are consistent with the well-established profile of guselkumab in psoriasis," said Alyssa Johnsen, M.D., Ph.D., Vice President, Rheumatology Disease Area Leader, Janssen Research Development, LLC. "We are excited to share the data on guselkumab in psoriatic arthritis as we continue to advance our research in this disease and bring more treatment options to psoriatic arthritis patients in need."
</p>  	<p>In a separate study, data from DISCOVER-1 and DISCOVER-2 were analysed as part of a network meta-analysis that compared the efficacy and safety of guselkumab to other targeted biologic therapies for PsA. Twenty-six Phase 3 studies were included comparing the impact of 13 targeted therapies for PsA on ACR 20/50/70 response, Psoriasis Area Severity Index (PASI) 75/90/100 response, HAQ-DI score, resolution of enthesitis, resolution of dactylitis, AEs and serious AEs. The analysis is being shared as an abstract (Abstract AB0820) during the EULAR E-Congress.<sup>7</sup></p>  	<p class="bwalignc">ENDS 
<div id="nativendo-nachrichten-inarticle"></div></p>  	<p>  		<sup></sup><i>Dr Christopher Ritchlin is a paid consultant for Janssen. He has not been compensated for any media work.</i></p>  	<p>  		<b>Key definitions</b></p>  	<p>  		<sup>a </sup>IGA score of 0 or 1, and a <span class="bwuline"></span>2 grade reduction in body surface area affected.<sup>8
<br/>b</sup> The van der Heijde modified Sharp score (modified for use in PsA) is a method used to assess and rate erosions and joint space narrowing in radiographs of hands and feet.<sup>9
<br/>c </sup>Resolution of enthesitis (inflammation of entheses which are the sites where tendons or ligaments insert into the bone) was defined as complete absence of enthesitis in any location measured by Leeds Enthesitis Index.<sup>8
<br/>d</sup> Resolution of dactylitis (the inflammation of a digit) was defined as complete absence of dactylitis in 20 sites (10 fingers, 10 toes) as measured by Dactylitis Severity Scale.<sup>8
<br/>e</sup> Patients were considered to have achieved minimal disease activity if fulfilling at least five of the following seven criteria: tender joint count 1 or less, swollen joint count 1 or less, PASI score 1 or less, patient pain visual analogue scale (VAS) score 15 or less, patient global disease activity VAS score 20 or less, HAQ-DI score 0.5 or less, and tender entheseal points 1 or less.<sup>4
<br/>f</sup> MDA is defined by low activity assessed by tender/swollen joint counts, tender entheseal points, PASI or body surface area, patient pain and global activity VAS, and functional evaluation by Health Assessment Questionnaire.<sup>10
<br/>g</sup> VLDA is defined as achieving all 7/7 MDA criteria.<sup>11
<br/>h</sup> HAQDI is a patient questionnaire that assesses physical function and disability across rheumatic diseases.<sup>8
<br/>i</sup> SF-36 is a patient-reported survey that measures functional health and wellbeing.<sup>8
<br/>j </sup>As part of SF-36, the PCS subscale is composed of four scales assessing physical function, role limitations caused by physical?problems, bodily pain, and general health.<sup>8
<br/>k </sup>MCS is composed of four scales assessing vitality, emotional impact, social functioning, and mental health.<sup>8</sup></p>  	<p>  		<b><span class="bwuline">About DISCOVER-1 (NCT03162796)</span></b><sup>8
<br/></sup>DISCOVER-1 is a randomised, double-blind, multicentre Phase 3 study evaluating the efficacy and safety of guselkumab administered by subcutaneous (SC) injection in participants with active psoriatic arthritis including those previously treated with biologic anti-TNF alpha agent(s). DISCOVER-1 evaluated 381 participants and continued through approximately one year.<sup>4</sup></p>  	<p>The study consisted of a screening phase of up to six weeks, a blinded treatment phase of 52 weeks that includes a placebo-controlled period from week 0 to week 24 and an active treatment period from week 24 to week 52. It also includes a safety follow-up phase of eight weeks after week 52 (week 52 to 60; 12 weeks from the last administration of study agent [at week 48] through to the final visit in the safety follow-up phase). Efficacy, safety, pharmacokinetic, immunogenicity and biomarker evaluations were performed in the study on a defined schedule.
</p>  	<p>  		<b><span class="bwuline">About DISCOVER-2 (NCT03158285)</span></b><sup>12
<br/></sup>DISCOVER-2 is a randomised, double-blind, multicentre Phase 3 study evaluating the efficacy and safety of guselkumab administered by SC injection in subjects with active psoriatic arthritis. DISCOVER-2 is evaluating 739 participants and continuing through approximately two years.<sup>5</sup></p>  	<p>The study consists of a screening phase of up to six weeks, a blinded treatment phase (approximately 100 weeks) that includes a placebo-controlled period from week 0 to week 24 and an active treatment period from week 24 to week 100. It also includes a safety follow-up phase of 12 weeks after the last administration of study agent. Efficacy, health economics, safety, pharmacokinetics, immunogenicity, biomarker and pharmacogenomics evaluations are being performed in the study on a defined schedule.
</p>  	<p>  		<b><span class="bwuline">About Psoriatic Arthritis
<br/></span></b>Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease characterised by peripheral joint inflammation, enthesitis, dactylitis, axial disease and the skin lesions associated with psoriasis.<sup>13</sup> Studies show that up to 30 percent of people with psoriasis also develop PsA.<sup>14 </sup>The disease causes pain, stiffness and swelling in and around the joints; it commonly appears between the ages of 30 and 50, but can develop at any time.<sup>14,15</sup> Though the exact cause of PsA is unknown, genes, the immune system and environmental factors are all believed to play a role in the onset of the disease.<sup>15</sup></p>  	<p>  		<b><span class="bwuline">About TREMFYA<sup></sup>(guselkumab)</span></b><sup>6
<br/></sup>Developed by Janssen, guselkumab is the first approved monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. Guselkumab is approved as a prescription medicine in the EU, U.S., Canada, Japan and a number of other countries worldwide for the treatment of adult patients with moderate to severe plaque psoriasis who may benefit from injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet [UV] light). It is approved as a prescription medicine in Japan and Brazil for the treatment of adult patients with active PsA. IL-23 is an important driver of the pathogenesis of inflammatory diseases such as psoriasis and PsA.<sup>16 </sup>In psoriasis, guselkumab is administered as a 100 mg SC injection once every 8 weeks, after starter doses at weeks 0 and 4.
</p>  	<p>The Janssen Pharmaceutical Companies of Johnson Johnson maintain exclusive worldwide marketing rights to TREMFYA<sup></sup></p>  	<p>  		<strong><span class="bwuline">Important Safety Information
<br/></span></strong>Very common (>10%) and common AEs (>1%) in controlled periods of clinical studies with guselkumab were upper respiratory infections, gastroenteritis, herpes simplex infections, tinea infections, headache, diarrhoea, urticaria, arthralgia and injection site erythema. Most were considered to be mild and did not necessitate discontinuation of study treatment.
</p>  	<p>Please refer to the Summary of Product Characteristics for full prescribing information for guselkumab: https://www.medicines.org.uk/emc/medicine/34321  	</p>  	<p>AEs should be reported. This medicinal product is subject to additional monitoring and it is, therefore, important to report any suspected AEs related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. AEs should also be reported to Janssen-Cilag Ltd on 01494 567447.
</p>  	<p>  		<b><span class="bwuline">About the Janssen Pharmaceutical Companies of Johnson Johnson
<br/></span></b>At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular Metabolism, Immunology, Infectious Diseases Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
</p>  	<p>Learn more at <span class="bwuline">www.janssen.com/emea</span></p>  	<p>Follow us at <span class="bwuline">www.twitter.com/JanssenEMEA</span></p>  	<p>Janssen-Cilag International NV, the marketing authorisation holder for TREMFYA<sup></sup> in the EU, and Janssen Research Development, LLC, are part of the Janssen Pharmaceutical Companies of Johnson Johnson.
</p>  	<p>  		<b><span class="bwuline">Cautions Concerning Forward-Looking Statements
<br/></span></b><i>This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding ongoing and planned development efforts involving TREMFYA<sup></sup> (guselkumab) as a treatment for adult patients with active psoriatic arthritis. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen Research Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson Johnson. None of the Janssen Pharmaceutical Companies nor Johnson Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.</i></p>  	<p class="bwalignc"></p>  	<p>  		<b>References:</b></p>  	<ol class="bwlistdecimal">  		<li>Ritchlin, C, <i>et al. </i>Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study of Patients who were Biologic-Naïve or TNFa Inhibitor-Experienced. SAT0397. Presented at the 2020 EULAR E-Congress June 3-6.
</li>  		<li>McInnes, I, <i>et al. </i>Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through Week 52 of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis. SAT0402. Presented at the 2020 EULAR E-Congress June 3-6.
</li>  		<li>Business Wire. Janssen Seeks to Expand Use of TREMFYA<sup></sup> (guselkumab) in the Treatment of Adults With Active Psoriatic Arthritis. Available at: https://www.businesswire.com/news/home/20191022006172/en/Janssen-Seeks-Expand-TREMFYA%C2%AE%E2%96%BC-guselkumab-Treatment-Adults. Accessed May 2020.
</li>  		<li>Deodhar A, <i>et al.</i>Guselkumab in Patients with Active Psoriatic Arthritis who were Biologic-naive or had Previously Received TNFa Inhibitor Treatment (DISCOVER-1): a Double-blind, Randomised, Placebo-controlled Phase 3 Trial. <i>The Lancet</i> 2020;395:1115-1125.
</li>  		<li>Mease PJ, <i>et al. </i>Guselkumab in Biologic-naive Patients with Active Psoriatic Arthritis (DISCOVER-2): A Double-blind, Randomised, Placebo-controlled Phase 3 Trial. <i>The Lancet</i> 2020;395:1126-1136.
</li>  		<li>European Medicines Agency. TREMFYA Summary of Product Characteristics. 2019. Available at: https://www.medicines.org.uk/emc/medicine/34321. Accessed May 2020.
</li>  		<li>McInnes, I, <i>et al</i>. Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systemic Literature Review and Network Meta-Analysis. (AB0820). Presented at the 2020 EULAR E-Congress June 3-6.
</li>  		<li>Clinicaltrials.gov. A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-Tumor Necrosis Factor (TNF) Alpha Agent(s) (DISCOVER-1). Identifier: NCT03162796. Available at: https://clinicaltrials.gov/ct2/show/NCT03162796. Accessed May 2020.
</li>  		<li>van der Heijde D, <i>et al.</i>Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis. 2005;64:ii61-ii64.
</li>  		<li>Gossec, L, <i>et al. </i>Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. <i>J Rheumatol</i> 2018;45:6-13.
</li>  		<li>Coates, L, <i>et al.</i> Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab. Abstract 2548. Presented at the 2017 ACR/ARHP Annual Meeting. Available at: https://acrabstracts.org/abstract/validation-of-new-potential-targets-for-remission-and-low-disease-activity-in-psoriatic-arthritis-in-patients-treated-with-golimumab/. Accessed May 2020.
</li>  		<li>Clinicaltrials.gov. A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis (DISCOVER-2). Identifier: NCT03158285. Available at: https://clinicaltrials.gov/ct2/show/NCT03158285. Accessed May 2020.
</li>  		<li>Belasco J and Wei N. Psoriatic Arthritis: What is Happening at the Joint? <i>Rheumatol Ther</i> 2019;6:305-315.
</li>  		<li>National Psoriasis Foundation. Statistics. Available at: https://www.psoriasis.org/content/statistics. Accessed May 2020.
</li>  		<li>National Psoriasis Foundation. About Psoriatic Arthritis. Available at: https://www.psoriasis.org/about-psoriatic-arthritis. Accessed May 2020.
</li>  		<li>Benson JM, <i>et al.</i> Discovery and Mechanism of Ustekinumab. <i>MAbs</i> 2011;3:535.
</li></ol>  	<p>CP-156282
<br/>June 2020 </p><p><img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&sty=20200603005461r1&sid=gefi2&distro=ftp"/></p><p id="mmgallerylink"><span id="mmgallerylink-phrase">View source version on businesswire.com: </span><span id="mmgallerylink-link">https://www.businesswire.com/news/home/20200603005461/en/</span></p><p>Contacts:</p><p>  		<b>Media contact: </b><br/>Kevin Veninga
<br/>Mobile: +31 61526 8214
<br/>KVeninga@ITS.JNJ.com  	</p>  	<p>  		<b>Investor contacts: </b><br/>Chris DelOrefice
<br/>Office: +1 (732) 524-2955
</p>  	<p>Jennifer McIntyre
<br/>Office: +1 (732) 524-3922
</p></div><div class="smartbroker--text"><span title="Jetzt für 0€ handeln - auf Smartbroker.de" class="nadT extern href cursor_pointer" data-nid="0" data-nad="650">Jetzt für 0€ handeln - auf Smartbroker.de</span></div></div><div class="article--copyright">&copy;&nbsp;2020&nbsp;Business Wire</div><div class="article--footer"><a href="http://www.facebook.com/sharer.php?u=https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm"
               title="Auf Facebook Teilen" target="_blank"><span title="Auf Facebook Teilen" class="fn-icon-fb"></span></a><a href="https://twitter.com/intent/tweet?source=webclient&url=https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm%2F&text=New First-in-Class Phase 3 TREMFYA? (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52"
               title="Tweeten" target="_blank"><span title="Tweeten" class="fn-icon-twitter"></span></a><a href="https://www.xing.com/app/user?op=share;url=https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm"
               title="Auf Xing Empfehlen" target="_blank"><span title="Auf Xing Empfehlen" class="fn-icon-xing"></span></a><a href="https://www.linkedin.com/shareArticle?mini=true&url=https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm&title=deintitel"
               title="Auf LinkedIn Teilen" target="_blank"><span title="Auf LinkedIn Teilen" class="fn-icon-in"></span></a><a href="whatsapp://send?v=2&text=New First-in-Class Phase 3 TREMFYA? (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52 https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm"
               title="In WhatsApp Teilen" class="only-on-mobile"><span title="WhatsApp" class="fn-icon-whatsapp"></span></a><a href="https://share.flipboard.com/bookmarklet/popout?v=2&title=New First-in-Class Phase 3 TREMFYA? (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52&url=https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm"
               title="FlipBoard" target="_blank"><span title="FlipBoard" class="fn-icon-flipboard"></span></a><a href="https://getpocket.com/edit?url=https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm"
               title="GetPocket" target="_blank"><span title="GetPocket" class="fn-icon-getpocket"></span></a><span data-nid="49826080" class="fn-icon-print-2 on-click--print-article" title="Druckansicht"></span><span title="Schrift größer" class="fn-icon-font-incr on-click--incr-font-size"></span><span title="Schrift kleiner" class="fn-icon-font-decr on-click--decr-font-size"></span></div><div id="bookmarks_data" class="data"
             data-vibrant="True"
             data-nachrichtid="49826080"
             data-artikeladresse="https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm"
             data-artikeladresseurlencoded="https%3a%2f%2fwww.finanznachrichten.de%2fnachrichten-2020-06%2f49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm"></div></div></div></div></div><div class="sbSpalteR"><div id="dmr1"></div><div id="yoc_intext_middle_1_HB"></div><div id="yoc_general_middle_1_HB"></div><div id="sban2"></div><div id="WAd_NewsKnockouts" class="lazy-widget" data-path="/w/ad_newsknockouts/49826080?tab=0"></div><div id="W70" class="lazy-widget" data-path="/w/70/49826080?tab=4"></div><div id="W78" class="lazy-widget" data-path="/w/78/49826080?tab=0"></div><div id="W73" class="lazy-widget" data-path="/w/73/49826080?tab=0"></div><div id="dmr2"></div><div id="yoc_intext_middle_2_HB"></div><div id="yoc_general_middle_2_HB"></div><div id="sban3"></div></div><div class="sbSpalteL"></div><div class="sbSpalteR"></div></div><div id='sist1'></div><div id='yoc_outofpage_HB'></div><div id="fuss novibrant"><div id="fusszeile-links" class="seitenelement main">Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von <span class="sprite ls cursor_pointer on-click--partner" title="Lang &amp; Schwarz" data-val="lang-und-schwarz"></span>und <span class="sprite tg cursor_pointer on-click--partner" title="Tradegate" data-val="tradegate"></span></div><div class="clr"></div><div id="dban2"></div><div id="cban1"></div><div id="yoc_bottom_HB"></div><div id="footer-sozial"><div id="footer_version">FNRD-2.615.0</div><div id="seiten-bewertung"><div>Wie bewerten Sie die aktuell angezeigte Seite?</div><span class="vorheriger">sehr gut</span><span class="buttons" data-val='/service/seitenbewertung.htm'><span class="on-click--rate-site">1</span><span class="on-click--rate-site">2</span><span class="on-click--rate-site">3</span><span class="on-click--rate-site">4</span><span class="on-click--rate-site">5</span><span class="on-click--rate-site">6</span></span><span class="naechster">schlecht</span><span class="buttons btnProblem"><span style="margin-left: 15px" class="on-click--show-fancy-box" data-val="/service/problembericht.htm" title="Problem melden">Problem melden</span></span></div><div id="footer_social"><div class='facebookbuttons social-media-wrapper'><a class='sprite icon icon-flike facebookfanwerden' title='Jetzt Fan werden!' href='https://www.facebook.com/finanznachrichten'></a><a class='fb-share sprite empfehlenimage' target='_blank' href='https://www.facebook.com/sharer/sharer.php?u=https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm'></a></div><div class='twitterbutton social-media-wrapper'><div class='sprite twitterimage cursor_pointer' data-url='https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm' data-text='New First-in-Class Phase 3 TREMFYA? (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52'></div></div></div><div class="clear"></div></div><div class="sb-disclaimer"><b>Werbehinweise: </b>Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. 
    Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, 
    bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen 
    Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu 
    verstehen sein kann.
</div><div id="fusszeile" class="footer-navi"><div class="footer-scroll-top" title="Nach oben"><i class="icon fn-icon-scroll-top"></i></div><div class="footer-logo"><div></div><a href="/"><img src="https://fns1.de/img/logo_slogan.svg" alt="FinanzNachrichten.de" /></a></div><div class="footer-top"><div class="lnks"><a href="https://www.finanznachrichten.de/aktienkurse-index/dax-30.htm" title="DAX">DAX</a><a href="https://aktienkurs-orderbuch.finanznachrichten.de/" title="Xetra-Orderbuch">Xetra-Orderbuch</a><a href="https://www.finanznachrichten.de/nachrichten/ad-hoc-mitteilungen.htm" title="Ad hoc-Mitteilungen">Ad hoc-Mitteilungen</a><a href="https://www.finanznachrichten.de/nachrichten-index/uebersicht.htm" title="Nachrichten Börsen">Nachrichten Börsen</a><a href="https://www.finanznachrichten.de/nachrichten/empfehlungen.htm" title="Aktien-Empfehlungen">Aktien-Empfehlungen</a><a href="https://www.finanznachrichten.de/nachrichten-branche/uebersicht.htm" title="Branchen">Branchen</a><a href="https://www.finanznachrichten.de/nachrichten-medien/uebersicht.htm" title="Medien">Medien</a><a href="https://www.finanznachrichten.de/nachrichten/suche-medienarchiv.htm" title="Nachrichten-Archiv">Nachrichten-Archiv</a><div class="rss"><a href="https://www.finanznachrichten.de/service/rss.htm">RSS-News von FinanzNachrichten.de</a></div></div></div><div class="footer-bottom"><a href="https://www.finanznachrichten.de/service/presse.htm" rel="nofollow" title="Presse" class="fst">Presse</a><a href="https://www.finanznachrichten.de/service/impressum.htm" rel="nofollow" title="Impressum | AGB | Disclaimer | Datenschutz">Impressum | AGB | Disclaimer | Datenschutz</a><a href="https://www.finanznachrichten.de/service/mediadaten.htm" rel="nofollow" title="Mediadaten" class="lst"><span class="fett">Mediadaten</span></a></div></div></div><div id="smartbroker--head"><span class="on-click--partner sprite smartbroker-logo" data-val="smartbroker-head" title="Der Online Broker von Deutschlands größter Finanzcommunity"></span><span class="on-click--partner sprite smartbroker1" data-val="smartbroker-head" title="Jetzt für 0€ handeln!"></span></div></div><div id="url-css" class="data" data-all="https://fns1.de/css/fn211.css"></div><div id="model_data" class="data" data-realtime="False" data-tickernews="True"></div><div id="signalr_data" class="data" data-url="https://rt.finanznachrichten.de/signalr"></div><div id="ivw_data" class="data" data-zaehlcode="news-01"></div><div id="suchhilfe_data" class="data" data-url="https://www.finanznachrichten.de"></div><noscript><img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=798877413578193&ev=PageView&noscript=1" /></noscript><span id="ads_data" class="data"
      data-targeting-url="https://www.finanznachrichten.de/nachrichten-2020-06/49826080-new-first-in-class-phase-3-tremfya-guselkumab-data-demonstrate-improvement-in-psoriatic-arthritis-joint-and-skin-symptoms-at-week-52-004.htm"
      data-targeting-keywords="[&quot;New&quot;,&quot;First-in-Class&quot;,&quot;Phase&quot;,&quot;3&quot;,&quot;TREMFYA?&quot;,&quot;(guselkumab)&quot;,&quot;Data&quot;,&quot;Demonstrate&quot;,&quot;Improvement&quot;,&quot;in&quot;,&quot;Psoriatic&quot;,&quot;Arthritis&quot;,&quot;Joint&quot;,&quot;and&quot;,&quot;Skin&quot;,&quot;Symptoms&quot;,&quot;at&quot;,&quot;Week&quot;,&quot;52&quot;]"
      data-targeting-bereich="artikel_index"
      data-topbanner="True"
      data-articlebanner="True"
      data-leftsidebanner="False"></span><div id='div-gpt-ad-1479204326049-4'></div><a id="ads_wp" href="#" target="_blank"></a><div id="dsky1"></div><div id="dsky"></div></div><div class="modal fade" id="dialogbox" tabindex="-1" role="dialog" aria-hidden="true"><div class="modal-dialog"><div class="modal-content" id="dialogboxcontent"></div></div></div><script type="text/javascript">(function(){var t=document.getElementsByTagName("head")[0]||document.documentElement,n=document.createElement("script"),i;n.src="https://fns1.de/js/foot194.js";i=!1;n.onload=n.onreadystatechange=function(){i||this.readyState&&this.readyState!=="loaded"&&this.readyState!=="complete"||(i=!0,n.onload=n.onreadystatechange=null,t&&n.parentNode&&t.removeChild(n))};t.insertBefore(n,t.firstChild)})()</script><script language="javascript" src="/scripts/58051a226292c9da91b70591caa0e9c22a7ac132.js"></script><script src="https://www.gstatic.com/firebasejs/6.3.3/firebase-app.js"></script><script src="https://www.gstatic.com/firebasejs/6.3.3/firebase-messaging.js"></script><script>firebase.initializeApp({
            apiKey: "AIzaSyAgKusdydsLP0kHKJjBV7bGyg18uJZnjBo",
            authDomain: "finanznachrichten-8126c.firebaseapp.com",
            databaseURL: "https://finanznachrichten-8126c.firebaseio.com",
            projectId: "finanznachrichten-8126c",
            storageBucket: "finanznachrichten-8126c.appspot.com",
            messagingSenderId: "303111472022",
            appId: "1:303111472022:web:6d8b3fe9658bf905"
        });</script></body></html>